^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Cervical Cancer
    Drug:Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

    Published date:
    10/19/2019
    Excerpt:
    Consistent with the in vitro data, when the activity of copanlisib and neratinib was evaluated in vivo against CVX-5, a PIK3CA-mutated cervical tumor, we found single agent copanlisib and neratinib to be active but only transiently effective in controlling tumor growth (Fig. 4B). Remarkably, the combination of the 2 inhibitors induced a durable tumor growth inhibition when compared to single agent copanlisib and neratinib (P = 0.02 and P = 0.006, respectively)...
    DOI:
    10.1073/pnas.1911385116